Log in
Request a free trial
Request a free trial
Log in
Products
Solutions
Data
News & Analysis
About
News & Analysis
driven by the PitchBook Platform
subscribe
Private Equity
Venture Capital
M&A
More
reports
videos
All
Report Center
Industry Updates
In the Spotlight
Blog
reports
Boston Scientific Buying Vessix, Providing an Exit for Multiple VCs
November 09, 2012
Share:
Boston Scientific
(NYSE: BSX) is acquiring venture-funded
Vessix Vascular
, maker of a catheter-based device to treat uncontrolled hypertension. The purchase price includes an upfront payment of $125 million, with milestone payments of up to $400 million. Vessix snagged its final financing in August 2011, landing $23 million of Series B funding from
Edmond de Rothschild Investment Partners
,
OrbiMed Advisors
,
CDF Dinova Venture Partners
,
NeoMed Management
,
Christopher Weil & Company
and
Fjord Ventures
.
Vessix Vascular
Surgical Devices
Laguna Hills, CA
$125 million
Corporate Acquisition
VIEW DETAILS
Sellers
CDF Dinova Venture Partners
Christopher Weil & Company
Edmond de Rothschild Investment Partners
Fjord Ventures
NeoMed Management
OrbiMed Advisors
Buyer
Boston Scientific
(NYSE: BSX)
Legal Advisor
Latham & Watkins
Share:
Tags
Private Equity
Venture Capital
related
Here are the PE & VC firms most affected by the solar eclipse
PE doubles down on VC-backed startups
Vision Fund 101: Inside SoftBank's $93B vehicle
VC & PE analyst compensation: pre-MBA vs. post-MBA
MOST READ ARTICLES
The sky's the limit: 3 VC-backed companies making flying cars
Can VCs keep pace with the ICO market?
Investor Spotlight: The rapid rise of Thoma Bravo
VC investment in US agtech keeps growing [datagraphic]
Timeline: In seven years, WeWork built a $21B co-working empire
trending reports
3Q 2017
PitchBook Artificial Intelligence & Machine Learning Market Map
August 10, 2017
1H 2017
VC Valuations Report
August 09, 2017
A better way to do
VC, PE and M&A
The PitchBook Platform
